Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to -$30.9 million.

  • Collegium Pharmaceutical's Cash from Investing Activities rose 8760.14% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.2 million, marking a year-over-year increase of 8165.86%. This contributed to the annual value of -$287.8 million for FY2024, which is 30637.04% down from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Cash from Investing Activities stood at -$30.9 million, which was up 8760.14% from -$2.9 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Cash from Investing Activities ranged from a high of -$113000.0 in Q3 2022 and a low of -$572.2 million during Q1 2022
  • In the last 5 years, Collegium Pharmaceutical's Cash from Investing Activities had a median value of -$3.8 million in 2023 and averaged -$51.5 million.
  • In the last 5 years, Collegium Pharmaceutical's Cash from Investing Activities tumbled by 13358621.5% in 2022 and then soared by 9996.92% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Cash from Investing Activities (Quarter) stood at -$515000.0 in 2021, then plummeted by 82.52% to -$940000.0 in 2022, then tumbled by 2569.89% to -$25.1 million in 2023, then skyrocketed by 53.13% to -$11.8 million in 2024, then crashed by 162.44% to -$30.9 million in 2025.
  • Its Cash from Investing Activities was -$30.9 million in Q3 2025, compared to -$2.9 million in Q2 2025 and -$9.7 million in Q1 2025.